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Background: Levetiracetam (LEV) is an antiepileptic drug with a favorable tolerability and safety profile with little or
no effect on liver function.
Case presentation: Here, we reported an epileptic pediatric patient who developed a significant elevation in
serum alkaline phosphatase level (ALP) during LEV monotherapy. Moreover, the serum ALP level was surprisingly
decreased to normal after LEV discontinuation. The Naranjo Adverse Drug Reaction Probability Scale score was 6,
indicating firstly LEV was a probable cause for the increased serum ALP.
Conclusions: Cautious usage and concerns of the LEV-associated potential ALP elevation should be considered
when levetiracetam is prescribed to epilepsy patients, especially pediatric patients.
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Levetiracetam (LEV), structurally similar to the noo-
tropic drug piracetam, is an anticonvulsant medication
used for epilepsy treatment. It has been approved by the
US Food and Drug Administration as adjunctive therapy
for partial seizures in adult and children over 4 years of
age with favorable tolerability and safety [1,2]. Moreover,
previous studies have been indicated that its efficacy and
safety are available in infant and pediatric patients
younger than 4 years of age as well [3,4]. It has recently
been approved in the European Union as a monotherapy
treatment for partial seizures, or as an adjunctive ther-
apy for partial, myoclonic and tonic-clonic seizures [5].
The exactly underlying mechanisms by which LEV
exerts its antiepileptic effect have not yet completely
understood. Nevertheless, the drug binding to SV2A, a
synaptic vesicle protein [6], inhibits nerve conduction
across synapses [7]. The common untoward reactions of
LEV include asthenia, convulsion, dizziness and somno-
lence [8]. However, the liver enzyme induction effect of
LEV has never been literally reported before. Here, we* Correspondence: huangyaling12@yahoo.com.cn
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reproduction in any medium, provided the orpresented the first case in which elevated serum ALP
was highly associated with LEV administration.
Case presentation
A 10-month-old Han Chinese girl (weight 9 kg) with a
history of head trauma was treated conservatively after
being diagnosed as intracranial hemorrhage (brain com-
puted tomography scan, brain CT). The patient had been
suffered from convulsive attacks (more than 10 episodes/
day in the recent 7 days) for 1 week when she was admit-
ted to the Department of Pediatrics, Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology. The seizure was characterized as parox-
ysmal attacks of perioral cyanosis and limbs convulsion,
lasting for 2 minutes with spontaneous remission. Her
vital signs was stable and within normal limits, and phy-
sical and neurological examination revealed no remark-
able abnormalities.
Brain CT showed left parietal lobe malacia (2.5 ×
2.4 cm) and left parietal bone fracture (Figure 1). Mean-
while, the interictal electroencephalogram (EEG) indi-
cated rhythmic spikes in the left central, parietal and
temporal areas (Figure 2A). Routine full blood count
and blood biochemistry were normal (serum ALP 162
U/L; <500 U/L reference range, Figure 3 and Additional
file 1). Based on her disease courses, clinical presenta-
tions and auxiliary examinations (CT and EEG),td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Brain CT. (A) 2.5 × 2.4 cm low density area in left parietal lobe; (B) the interrupted skull continuity in left parietal bone and
left occipital.
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informed consent from the patient’s parents, LEV was
administrated at an initial dosage of 9.25 mg/kg/d, then
13.8 mg/kg/d, 18.5 mg/kg/d for 1 week, respectively. A
final dosage of 27.8 mg/kg/d was prescribed for main-
tenance therapy. The dose was increased gradually while
the patient was seizure-free by the end of the
second week after LEV administration.
Five months after LEV treatment, an elevation of
serum ALP level (1613 U/L) was accidentally found
from a periodical blood biochemistry test without any
other abnormalities. One week later, the repeated la-
boratory test showed that serum ALP level was signifi-
cantly increased to 4557U/L, accompanied by slightly
elevated levels of creatine kinase (81 U/L, 26-140 U/L),
creatine kinase-MB activity (50 U/L, 0-24 U/L), lactate
dehydrogenase (320 U/L, 109-245 U/L) and bone ALP
(>300 U/L, 0-200 U/L). However, no discomfort or
seizure activity was observed in this patient. Other
related auxiliary examinations included parathyrin level
(20.9 pg, 15-68.3 pg), abdominal ultrasound and CT
(liver, hepatobiliary system, gallbladder, spleen and kid-
ney), lower extremity long bones X-ray and EEG
(Figure 2B) were all normal. Also, no concomitant
symptoms and other changes could explain the ele-
vated serum ALP. Therefore, considering the possibility
that LEV might be associated with the elevated serum
ALP, LEV was discontinued. Surprisingly, the serum
ALP level was decreased to 1156 U/L 10 days later.
Twenty days after the discontinuation, the patient’s
serum ALP level returned to normal (423 U/L). Six
months follow-up indicated that the patient was fully
recovered, manifesting no recurrent seizure attack orliver function abnormality. She was well developed and
nourished during that period, observing from her
height, weight, and body mass index.
Naranjo Adverse Drug Reaction Probability Scale [9]
was employed to assess the probability correlation of
LEV administration and elevated serum ALP. A score of
6 was obtained (Additional file 2), demonstrating LEV
was a “probable” cause for the serum ALP elevation, and
LEV even possibly led to liver function abnormality al-
though LEV rechallenge was not executed in this
patient.
Discussion and conclusions
Here, we reported a pediatric epilepsy patient who
developed elevated serum ALP after LEV treatment. To
our knowledge, this is the first report about probable
LEV-associated ALP elevation. Before LEV was admini-
strated, the patient’s serum ALP level was normal (162
U/L). The patient was asymptomatic during the inter-
vening period, thus, no other medication was added. As
LEV was the only medication for the patient, it was sus-
pected to be the offending agent responsible for the
increased ALP level. Moreover, the serum ALP level
decreased gradually and returned to normal after the
discontinuation of LEV therapy.
The serum ALP activity is commonly measured in
clinical chemistry laboratories. Increased values are
often associated with disorders of the skeletal or hepa-
tobiliary system, or other possibilities such as leukemia
and hyperthyroidism [10]. In our case, all of these po-
tentialities were ruled out by the clinical presentations
and auxiliary examination results for parathyrin level,
liver, hepatobiliary system, gallbladder, spleen, kidney
Figure 2 Routine EEG before and after antiepileptic therapy. (A) Rhythmic spikes in the left central, parietal and temporal areas. (B) Normal
rhythm of brain waves after antiepileptic treatment.
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itionally, history of toxic substances exposure and
other drug abuse was absent. Besides, the patient’s
increased serum ALP lever was rapidly returned to
normal range after discontinuation of LEV, indicating
the association between elevated serum ALP and LEV
treatment should not be coincidental. Furthermore, the
Naranjo Adverse Drug Reaction Probability Scale as-
sessment further confirmed that LEV was a “probable”
cause for the serum ALP elevation.
Serious liver function impairment could be rarely
observed in patients taking AEDs. Among the traditional
AEDs, valproate, which requires routine blood monitor-
ing, can cause hepatotoxicity. Felbamate is the only
second-generation AEDs associated with hepatotoxicitythat may be fatal. However, liver function impairment has
never been reported with LEV. LEV shows rapid absorp-
tion, does not bind serum proteins and has linear pharma-
cokinetics. More than 60% of absorbed LEV can be
excreted by the kidneys, approximately 25% is metabolized
by metabolized through esterase’s in the blood, less than
3% is plasma protein-bound [11]. Previous study even
reported that LEV might affect bone metabolism of both
neurologically impaired children and healthy children
[12]. Moreover, increased clearance of LEV is reportedly
associated with younger age [11]. Although LEV rarely
distributes into liver and skeletal sites, nor has displayed
any enzyme induction effects in human liver cell tissue
[11], it is necessary to present this case and raise the con-
cern of potential hepatotoxicity of LEV.
Figure 3 Main indicators of liver function and kidney function before, during and after LEV administration.
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http://www.biomedcentral.com/1471-2377/12/97In summary, we introduced the first case which
showed elevated serum ALP level was highly associated
with LEV administration. However, it is difficult to con-
firm the relevance between LEV and serum ALP eleva-
tion. Further study is needed extremely to assess the
potential hepatotoxicity of LEV in pediatric patients.Consent
Written informed consent was obtained from the pa-
tient and her parents for publication of this Case report
and any accompanying images. A copy of the written
consent is available for review by the Series Editor of
this journal.Additional files
Additional file 1: Biochemistry findings before, during and after
LEV treatment. WBC: white blood cells; RBC: red blood cells; PLT:
platelets; ALT: Alanine aminotransferase; AST: aspartate aminotransferase;
γGT: gamma glutamyltransferase; Creat: creatinine; CK: creatine kinase;
LDH: lactate dehydrogenase.
Additional file 2: Adverse drug reactions (ADRs) probability scale.
Abbreviations
LEV: Levetiracetam; AEDs: Antiepileptic drugs; ALP: Alkaline phosphatase;
EEG: Electroencephalogram; CT: Computed tomography scan.Competing interests
We confirm that we have read the Journal’s position on issues involved in
ethical publication and affirm that this report is consistent with those
guidelines. None of the authors have any conflict of interest to disclose.
Authors’ contributions
NX, LH, NL, AM, TW, YH contributed to the conception and design. NX, LH,
NL took care of the clinical data collection. NX, LH, AM, TW, YH coordinated
all the experiments and helped to draft the manuscript. All authors read,
revised and approved the final manuscript.
Acknowledgments
This work was supported by grant (200960323134) from the Wuhan Science
and Technology Bureau (to YH), grants 30870866, 81071021 and 31171211
from the National Natural Science Foundation of China (to TW), grant
81200983 from the National Natural Science Foundation of China (to NX)
and grant 2012B09 from the China Medical Foundation (to NX).
Author details
1Department of Neurology, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Hubei 430022, China.
2Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022
Hubei, China. 3Department of Neurology, General Hospital of Wuhan Iron
and Steel (Group) Corporation, 29 Yejin Avenue, Qingshan, Wuhan, Hubei
430080, China.
Received: 11 December 2011 Accepted: 17 September 2012
Published: 20 September 2012
References
1. Leppik IE: Issues in the treatment of epilepsy. Epilepsia 2001,
42(Suppl 4):1–6.
Xiong et al. BMC Neurology 2012, 12:97 Page 5 of 5
http://www.biomedcentral.com/1471-2377/12/972. Wheless JW: Levetiracetam in the treatment of childhood epilepsy.
Neuropsychiatr Dis Treat 2007, 3(4):409–421.
3. Krief P, Li K, Maytal J: Efficacy of levetiracetam in children with epilepsy
younger than 2 years of age. J Child Neurol 2008, 23(5):582–584.
4. Li S, Cao J, Xiao N, Cai F: Efficacy and safety of levetiracetam as an add-
on therapy in children aged less than 4 years with refractory epilepsy.
J Child Neurol 2010, 25(5):609–613.
5. Perucca E: Designing clinical trials to assess antiepileptic drugs as
monotherapy: difficulties and solutions. CNS Drugs 2008, 22(11):917–938.
6. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A,
Fuks B: The synaptic vesicle protein SV2A is the binding site for the
antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004,
101(26):9861–9866.
7. Rogawski MA: Diverse mechanisms of antiepileptic drugs in the
development pipeline. Epilepsy Res 2006, 69(3):273–294.
8. Briggs DE, French JA: Levetiracetam safety profiles and tolerability in
epilepsy patients. Expert Opin Drug Saf 2004, 3(5):415–424.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E,
Domecq C, Greenblatt DJ: A method for estimating the probability of
adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239–245.
10. Narayanan S: Serum alkaline phosphatase isoenzymes as markers of liver
disease. Ann Clin Lab Sci 1991, 21(1):12–18.
11. Dahlin MG, Wide K, Ohman I: Age and comedications influence
levetiracetam pharmacokinetics in children. Pediatr Neurol 2010,
43(4):231–235.
12. Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC:
Antiepileptic Drugs and Bone Metabolism in Children: Data from 128
Patients. J Child Neurol 2012, doi:10.1177/0883073812443005.
doi:10.1186/1471-2377-12-97
Cite this article as: Xiong et al.: Probable levetiracetam-related serum
alkaline phosphatase elevation. BMC Neurology 2012 12:97.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
